SCHLIEREN, Switzerland -- The Volpi Group, a 60-year-old optical electronics firm based in Schlieren, Switzerland, is collaborating with QIAGEN Instruments AG on the manufacture of the automated fluorescence imaging module used in QIAGEN's GeneReader[TM] next-generation sequencing (NGS) instrument. The benchtop GeneReader combines with other QIAGEN NGS products to provide the first seamless, fully automated Sample to Insight workflow.
Volpi optimized the GeneReader's automated imaging module at its precision engineering site in Zurich, Switzerland. The module for the QIAGEN instrument is manufactured at Volpi's production facility in Auburn, N.Y., U.S.A. Volpi specializes in the engineering and manufacture of optoelectronic modules for diagnostic, life science and other applications. These modules combine electronics with the detection and measurement of light, like the fluorescent light emitted by the GeneReader system when a biological marker is present in a patient sample.
The GeneReader NGS System provides the first complete Sample to Insight Next Generation Sequencing (NGS) solution designed for any laboratory to deliver actionable results. It offers the world's first truly end-to-end NGS workflow from primary sample to final report that provides a simpler, more cost-effective way for clinical testing to take advantage of the NGS technology and improve outcomes.
One of the first applications for GeneReader is the Actionable Insights Tumor Panel, the first of a family of panels powered by QIAGEN Clinical Insight (QCI), the company's clinical decision support solution for labs. The novel tumor gene panel targets 12 clinically actionable genes that are often analyzed in most of the prevalent types of cancer, including breast, ovarian, colorectal, lung and skin.